Today's Peptide News — August 2, 2026

Eli Lilly's once-weekly triple agonist retatrutide met its primary and key secondary endpoints in the Phase 3 TRIUMPH-1 trial, a randomized, double-blind, placebo-controlled study of 2,339 adults with obesity or overweight plus a weight-related comorbidity and without diabetes. At 80 weeks, mean body weight fell 19.0% on the 4 mg dose, 25.9% on 9 mg, and 28.3% on 12 mg, versus 2.2% for placebo. Nearly half of participants on the top dose (45.3%) lost at least 30% of their body weight, alongside improvements in cardiometabolic risk factors.

Retatrutide is engineered to activate three receptors at once — GIP, GLP-1, and glucagon — which appears to push efficacy beyond the dual-agonist standard set by tirzepatide. TRIUMPH-1 is considered pivotal evidence for an FDA filing, with TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (established cardiovascular disease) readouts expected later in 2026.

This is the strongest single peptide story of the day and an obvious PeptideWiki anchor. Suggested angle: a focused post on retatrutide's triple-agonist mechanism and how the TRIUMPH-1 numbers reset the benchmark for anti-obesity pharmacotherapy, with a short comparison to semaglutide and tirzepatide.

A University of Alberta team reported preclinical results in Cell Biomaterials for D-GK17, a stabilized mirror-image (D-amino acid) subunit derived from LL-37, the human host-defense peptide. The design shows broad-spectrum activity against bacterial and fungal pathogens, including ESKAPE organisms, and disrupts established biofilms in preclinical models. Just as notably, the peptide is reported to be stable, noncytotoxic, anti-inflammatory, and to promote wound healing.

The mirror-image approach matters because natural host-defense peptides are usually degraded quickly by proteases in the body; building the molecule from D-amino acids resists that breakdown while preserving activity. That combination of stability, low toxicity, and anti-biofilm action addresses several of the practical hurdles that have kept antimicrobial peptides from reaching the clinic.

Suggested angle: a PeptideWiki explainer on LL-37 and its engineered derivatives, using D-GK17 to illustrate why D-amino acid "mirror" peptides are a promising route around the antimicrobial-resistance crisis.

A bioRxiv preprint describes a computational, structure-guided pipeline that designs peptide- and protein-based inhibitors against three virulence-associated peptidases of Cryptococcus: Rim13 (a cysteine peptidase), May1 (aspartic), and CnMpr1 (metallo). Rather than killing the fungus outright, the inhibitors target the enzymes it uses to cause disease — an anti-virulence strategy. In an in vivo larval model, the peptides produced additive effects when combined with fluconazole and showed no host cell cytotoxicity.

Anti-virulence approaches are attractive because they apply less direct survival pressure on the pathogen, potentially slowing the emergence of resistance, and here the additive benefit with an existing antifungal points toward combination therapy. As a preprint the work is early and not yet peer-reviewed, which is worth flagging.

Suggested angle: a short PeptideWiki piece on designed peptidase-inhibitor peptides as an anti-virulence tactic, framing it as a template that could extend to other fungal and bacterial pathogens.

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157, TB-500, and five other peptides for possible inclusion on the 503A bulk-substances compounding list. The outcome directly shapes whether compounding pharmacies can legally prepare these popular research peptides for patients, an area that has grown rapidly amid consumer demand.

The meeting drew scrutiny because several newer panel members reportedly run or promote peptide businesses of their own, raising conflict-of-interest questions around how these substances are evaluated. For a readership tracking BPC-157 and TB-500, the regulatory framing here is as important as any efficacy data.

The FDA approved orforglipron (Foundayo; Eli Lilly) for chronic weight management in adults with obesity, or overweight adults with at least one weight-related comorbidity, used alongside diet and exercise. It is the first oral GLP-1 receptor agonist that can be taken at any time of day with no restrictions on food or water intake — a meaningful convenience advantage over injectable GLP-1s and over peptide-based oral formulations that require fasting windows.

Because orforglipron is a small molecule rather than a peptide, its arrival is notable for what it signals about the competitive landscape around peptide GLP-1 drugs: an easy-to-take daily pill could reshape access and adherence in the obesity market.

Novo Nordisk's investigational CagriSema — a fixed combination of the amylin analog cagrilintide and the GLP-1 agonist semaglutide — produced an average 20.4% body-weight reduction over 68 weeks in late-phase testing. The drug is not yet FDA approved but sits in late-stage development as of mid-2026, positioning it as Novo's leading answer to Lilly's tirzepatide and retatrutide.

The pairing is scientifically interesting because it combines two distinct peptide mechanisms — amylin and GLP-1 signaling — and offers a window into where the next generation of combination peptide therapeutics for obesity is heading.

New research suggests that eating an avocado each day may lower heart disease risk in adults with obesity by reducing the number of LDL particles circulating in the blood. LDL particle number is an increasingly emphasized marker of cardiovascular risk, sometimes tracking risk better than standard LDL cholesterol concentration alone.

The finding adds to a growing body of work on dietary fats and cardiometabolic health, pointing to a simple, food-based intervention that could complement medical therapy in a high-risk population.

Scientists have identified an immune response that may explain why statins cause muscle pain, weakness, and exercise intolerance in some patients — one of the most common reasons people stop taking these widely prescribed cholesterol drugs. Pinpointing an immune mechanism opens the door to predicting who is susceptible and potentially to interventions that preserve statin benefits while limiting muscle side effects.

Given how central statins are to cardiovascular prevention, a mechanistic handle on their muscle toxicity could improve adherence for millions of patients.

An AI-assisted counterexample has disproved the Jacobian conjecture in dimensions above two, while leaving the famous two-dimensional version of the problem unresolved. The conjecture, open for decades, is a landmark question in algebraic geometry, and the result is a striking example of machine assistance contributing to a genuine mathematical proof.

Beyond the specific result, it adds to a run of 2026 developments in which AI systems help settle long-standing problems, sharpening the debate over how computational tools are reshaping pure mathematics.